These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34211991)

  • 1. Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry.
    Kim HA; Lee SK; Oh S; Park EH; Park YB; Shin K
    Front Med (Lausanne); 2021; 8():689609. PubMed ID: 34211991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry.
    Kim HA; Lee E; Lee SK; Park YB; Shin K
    BioDrugs; 2020 Aug; 34(4):529-539. PubMed ID: 32696266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry.
    Kim HA; Lee E; Lee SK; Park YB; Lee YN; Kang HJ; Shin K
    Clin Exp Rheumatol; 2020; 38(2):267-274. PubMed ID: 31365335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with cause-specific discontinuation of long-term anti-tumor necrosis factor agent use in patients with ankylosing spondylitis: a retrospective cohort study.
    Nam B; Choi N; Koo BS; Kim J; Kim TH
    BMC Rheumatol; 2024 Aug; 8(1):39. PubMed ID: 39215338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry.
    Kim JW; Lee EA; Kim HA; Suh CH; Jung JY
    BioDrugs; 2022 May; 36(3):411-419. PubMed ID: 35349115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis.
    Lee JW; Kang JH; Yim YR; Kim JE; Wen L; Lee KE; Park DJ; Kim TJ; Park YW; Lee SS
    PLoS One; 2015; 10(7):e0131864. PubMed ID: 26176701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic retention rate and efficacy in patients with cluster-based phenotypes of ankylosing spondylitis: data from a Korean national biologics registry.
    Min HK; Kim HR; Lee SH; Kang KY; Park SH; Shin K; Kim J; Kwok SK
    Clin Exp Rheumatol; 2022 Sep; 40(9):1701-1707. PubMed ID: 34874838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
    Lee S; Park YJ; Lee JY
    J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Acute Anterior Uveitis in Ankylosing Spondylitis According to the Type of Tumor Necrosis Factor-Alpha Inhibitor and History of Uveitis: A Nationwide Population-Based Study.
    Ahn SM; Kim M; Kim YJ; Lee Y; Kim YG
    J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis.
    Gulyas K; Bodnar N; Nagy Z; Szamosi S; Horvath A; Vancsa A; Vegh E; Szabo Z; Szucs G; Szekanecz Z; Szanto S
    Eur J Health Econ; 2014 May; 15 Suppl 1():S93-100. PubMed ID: 24832840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry.
    Mease PJ; van der Heijde D; Karki C; Liu M; Park Y; Greenberg JD
    Rheumatol Ther; 2018 Dec; 5(2):537-550. PubMed ID: 30353387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KOBIO, the First Web-based Korean Biologics Registry Operated With a Unified Platform Among Distinct Disease Entities.
    Kim J; Koh JH; Choi SJ; Jeon CH; Kwok SK; Kim SK; Choi CB; Lee J; Lee C; Nam EJ; Park YB; Lee SS; Kim TH; Park SH; Koh EM; Yoo DH; Song YW; Kim HA; Shin K
    J Rheum Dis; 2021 Oct; 28(4):176-182. PubMed ID: 37476366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.